U.S. Healthcare Services Stock News

First quarter loss widens for Damora Therapeutics (DMRA) Damora Therapeutics (DMRA) reported first quarter results that drew attention, with a net loss of US$27.78 million for the period ended March 31, 2026, compared with US$2.53 million a year earlier. See our latest analysis for Damora Therapeutics. The share price has been volatile, with a 1 day share price return of 1.77% and year to date share price return of 15.95%. The 1 year total shareholder return is very large, but longer term...

MakeMyTrip (MMYT) is back in focus after its latest quarterly and full year 2026 results, where lower profit and an earnings miss contrasted with higher gross bookings, rising finance costs, and ongoing geopolitical pressures on travel demand. See our latest analysis for MakeMyTrip. The stock’s recent slide, including a 30 day share price return of down 6.82% and a year to date share price return of down 47.8%, contrasts sharply with a 3 year total shareholder return of 62.12%. This suggests...

Spire Global (SPIR) is back on investor radar after two business updates: an expanded Cirrus weather intelligence offering for energy traders and a new aircraft tracking data agreement with Amadeus IT Group. See our latest analysis for Spire Global. The share price has moved to US$21.16 after a 10.15% 1 day share price return and a 129.75% 90 day share price return, alongside a 1 year total shareholder return of 98.87%, reflecting strong momentum despite the recent earnings shortfall and...

In May 2026, Immunovant, Inc. reported a wider quarterly and full-year net loss, with fourth-quarter net loss rising to US$147.86 million and full-year net loss to US$505.61 million, while maintaining a cash balance above US$900 million and recording no revenue. At the same time, Immunovant released encouraging Week 16 data for its lead FcRn inhibitor IMVT-1402 in difficult-to-treat rheumatoid arthritis and discontinued batoclimab after Phase 3 failures, signaling a concentrated push behind...

Earlier in May 2026, Teva Pharmaceutical Industries presented new real-world data from its three-year IMPACT-TD Registry at the American Psychiatric Association meeting, revealing that young adults with mood disorders and tardive dyskinesia often face delayed recognition and low formal diagnosis rates despite substantial daily life impact. The findings underline a pronounced diagnostic gap in tardive dyskinesia for patients under 40, especially those aged 18–29, who report high psychological...

Earlier this week, ESAB introduced the Sentinel A70 PRO, its first premium flip-up automatic welding helmet for heavy industry, featuring dual flip-up functionality, advanced optics, integrated lighting, Bluetooth connectivity, and second-generation True-Color auto-darkening technology designed to enhance comfort and productivity. The launch underscores ESAB’s push to differentiate through higher-tech equipment at a time when analysts remain concerned about its limited organic revenue growth...

Popular (BPOP) has drawn fresh attention after two years of expanding net interest margin, strong quarterly results and annualized EPS growth of 30.9%, with recent options activity pointing to expectations of sharper share price moves. See our latest analysis for Popular. Recent governance changes at the annual meeting and a renewed performance focus from management sit alongside a 19.5% year to date share price return and a 50.5% 1 year total shareholder return, indicating momentum that...

Rising mortgage rates recently hit a one month high, stirring fresh worries about housing affordability and future demand. Griffon (GFF), a home construction materials company, dropped 3.9% in that session as investors reassessed sector risks. See our latest analysis for Griffon. Despite the recent drop on mortgage rate concerns, Griffon’s recent 7 day share price return of 3.7% and year to date share price return of 13.11% contrast with its 30 day share price decline of 6.83%, while the 1...

Brookfield Wealth Solutions Ltd. reported first-quarter 2026 results, with revenue of US$1.66 billion down from US$2.62 billion a year earlier and a wider net loss of US$609 million versus US$326 million, signaling a tougher operating period. The combination of sharply lower revenue and a much larger loss suggests the business is facing meaningful pressure on both growth and profitability drivers. Next, we’ll examine how this steep revenue drop and expanding loss profile shape Brookfield...

Record quarter puts HCI Group (HCI) in focus HCI Group (HCI) has drawn fresh attention after reporting the best first quarter in its history, pairing record profitability and cash flows with the start of a US$80 million share repurchase program. See our latest analysis for HCI Group. Despite the record quarter and active US$80 million buyback, recent share price returns have been mixed. The stock is down year to date but supported by a strong three year total shareholder return above 200%,...

Nuvalent recently presented pivotal ALKOVE-1 data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC and preliminary ARROS-1 data for zidesamtinib in ROS1-positive solid tumors other than NSCLC at the 2026 ASCO Annual Meeting, supporting its recent FDA NDA submission and ongoing Phase 3 ALKAZAR trial. An interesting angle is how zidesamtinib’s early results in ROS1-positive tumors beyond lung cancer highlight Nuvalent’s effort to broaden targeted therapy applications. We’ll now...

Earlier this week, Western Digital announced that its newest high-capacity Ultrastar DC HC6100 UltraSMR hard drives now integrate NIST-approved post-quantum cryptography, adding PQC-ready secure boot and firmware protection that are currently being qualified by multiple hyperscale customers. This move brings quantum-resistant security out of the lab and into production storage hardware, potentially redefining how AI data centers think about long-term device-level trust and infrastructure...

Solaris Energy Infrastructure (SEI) has just paired a nearly US$2b financing package with a sizable contract expansion, adding 130 MW and lifting its total contracted project investment by more than 60%. See our latest analysis for Solaris Energy Infrastructure. SEI’s share price has climbed 50.83% over the past 90 days and 47.77% year to date, while its 1 year total shareholder return of 178.07% points to strong momentum around the stock’s story. If this kind of contract-backed growth...

Target reported past first-quarter 2026 results with net sales of US$25,443 million, up from US$23,846 million a year earlier, while net income fell to US$781 million as earnings per share declined despite stronger comparable and digital sales. The company also raised its 2026 outlook, now projecting net sales growth around 4% versus 2025 and GAAP EPS near the high end of its prior US$7.50–US$8.50 range, underscoring management’s confidence while activist investors question board oversight...

What recent performance data says about ANI Pharmaceuticals stock With no single headline event driving attention, investors are looking at how ANI Pharmaceuticals (ANIP) has been trading recently and how that lines up with its current fundamentals and valuation signals. Over the past week, the stock gained about 6%, with returns of roughly 3% over the past month and 6% over the past 3 months. Year to date, ANI Pharmaceuticals is up about 5%, while its 1 year total return is around...

Rogers Corporation recently appointed Ali El-Haj as its President, Chief Executive Officer and a member of the Board, formalizing his role after serving as interim CEO and aligning his compensation with a US$750,000 base salary, a target annual incentive equal to base pay, and a US$5,000,000 long-term equity grant. The Board’s decision ties a substantial portion of El-Haj’s pay to multi-year restricted stock units, signaling a focus on longer-term performance and closer alignment between...

Earlier this month, UBS upgraded Alcoa Corporation to Buy, citing expectations that prolonged aluminium supply disruptions from the Middle East will tighten global markets and support the company’s pricing power and earnings potential. This upgrade highlights how geopolitical risks in key producing regions can rapidly reframe the outlook for an already cost‑pressured, capital‑intensive aluminium producer like Alcoa. We’ll now examine how UBS’s supply-disruption thesis interacts with Alcoa’s...

Broadstone Net Lease (BNL) entered the spotlight after first quarter 2026 earnings topped analyst expectations, with management reporting higher adjusted funds from operations, strong rent collections and high occupancy across its net lease portfolio. See our latest analysis for Broadstone Net Lease. Those results have helped keep momentum intact, with the share price at US$20.40 and a year to date share price return of 16.84%. The 1 year total shareholder return of 41.10% and 3 year total...

Encore Capital Group has recently completed and upsized two senior secured offerings, a US$750 million 6.625% note due 2032 and a €325 million floating rate note due 2033, to refinance existing higher‑coupon debt and repay revolving credit facility borrowings. By extending maturities and locking in a new mix of fixed and floating interest obligations, Encore is reshaping its capital structure and potentially influencing its future interest expense and financial flexibility. We’ll now examine...

In recent months, Voya Financial has reported double-digit earnings growth, strong margins in its Retirement and Investment Management segments, and continued cash returns to shareholders via buybacks and dividends, reinforcing confidence in its business performance. An interesting aspect is that this capital return has been paired with management’s emphasis on pricing and underwriting discipline in Employee Benefits, suggesting a focus on maintaining profitability as well as growth across...

Event overview and recent share performance MGIC Investment (MTG) has drawn attention after its share price closed at $26.00, with the stock down about 8% over the past month and slightly lower over the past 3 months. See our latest analysis for MGIC Investment. For context, MGIC Investment's 1 year total shareholder return of 2.3% contrasts with a year to date share price return that is down 10.8%. This suggests recent momentum has faded, even though longer term holders have still seen...

Dyne Therapeutics recently initiated the global, randomized, placebo-controlled Phase 3 FORZETTO trial of zeleciment rostudirsen (DYNE-251) in ambulatory males aged 4 to 18 with Duchenne muscular dystrophy amenable to exon 51 skipping, following alignment on the design with the U.S. FDA. A key feature for investors is that FORZETTO is intended as the confirmatory study to support converting a potential U.S. Accelerated Approval to traditional approval and to underpin ex-U.S. marketing...

Knight-Swift Transportation Holdings recently declared a quarterly cash dividend of US$0.20 per share, payable on June 22, 2026, while reporting first-quarter 2026 earnings that matched estimates but declined compared with the prior year. Despite softer recent profitability, management’s guidance for revenue growth and improved operating margins, alongside expansion in the less-than-truckload network, has renewed attention on how its freight platform could evolve. We will now examine how the...

Earlier in May 2026, Costamare Inc. reported Q1 2026 net income from continuing operations of US$81.9 million on revenues of US$211.1 million, both lower than the same period last year. The update also highlighted that container vessels remained the main profit driver while Costamare continued committing capital to four newbuild ships for delivery from late 2027 to 2028. We’ll now examine how this softer quarterly profitability, alongside continued fleet expansion, may influence Costamare’s...